Lisata Therapeutics, Inc. ( (LSTA) ) has released its Q4 earnings. Here is a breakdown of the information Lisata Therapeutics, Inc. presented to its investors.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, primarily through its novel product candidate, certepetide.
In its latest earnings report, Lisata Therapeutics highlighted promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer and announced the completion of enrollment in Qilu’s Phase 2 trial evaluating certepetide for first-line mPDAC treatment. The company also emphasized its strong cash position, extending its runway into the second quarter of 2026 with no debt.
Key financial metrics for 2024 included a total revenue of $1.0 million, primarily from a licensing agreement with Kuva Labs, and a net loss of $20.0 million, slightly improved from the previous year’s loss. Operating expenses decreased by 8.9% to $23.4 million, driven by reduced research and development costs and lower general and administrative expenses.
Strategically, Lisata is advancing its development portfolio with multiple clinical trials involving certepetide across various solid tumors and non-cancerous conditions. The company has secured several designations for certepetide, including Fast Track and Orphan Drug Designations, and is exploring collaborations to enhance its therapeutic applications.
Looking ahead, Lisata Therapeutics anticipates a data-rich year in 2025, with several clinical milestones expected. The management remains optimistic about the potential of certepetide to improve treatment outcomes in oncology and other therapeutic areas.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com